Impact of Dementia on Caregivers and Family Members
Quality of Life Results
In order to measure the quality of life, we used The Warwick-Edinburgh Mental Wellbeing scale on both the users and the primary contacts throughout the 7-week trial process. The Warwick-Edinburgh Mental Wellbeing scale was developed to enable the monitoring of mental wellbeing in the general population and the evaluation of projects, programmes and policies which aim to improve mental wellbeing.
Based on our comprehensive quality of life research on our 20 trial families over 7 weeks, we have generated the results as below:
We can see from the results that over 86% of participants showed an improving trend over time in the quality of life indicators for all the trial families. Most of the users feel more positive about the future, less isolated from their family and more interested in other people with Mylo. And family members tend to feel more relaxed and that they’ve had more energy to spare now than before getting Mylo.
Meanwhile, there are two quality of life indicators showing a downward trend. One is of thinking clearly, and the other is “I am able to make up my own mind about things”. We cannot deny that Mylo is designed to assist the elderly people with dementia. Even though Mylo may help people with dementia in many ways, the reality is that the medical condition they are suffering may still have a huge impact on certain aspects of life.
Overall, Mylo does appear to have a significant positive influence on the dementia users and their family members. The Mylo development team aims to continue our research and expand our sample size to further measure Mylo’s impact on the dementia population.